Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
- Goligher, E.C.
- Bradbury, C.A.
- McVerry, B.J.
- Lawler, P.R.
- Berger, J.S.
- Gong, M.N.
- Carrier, M.
- Reynolds, H.R.
- Kumar, A.
- Turgeon, A.F.
- Kornblith, L.Z.
- Kahn, S.R.
- Marshall, J.C.
- Kim, K.S.
- Houston, B.L.
- Derde, L.P.G.
- Cushman, M.
- Tritschler, T.
- Angus, D.C.
- Godoy, L.C.
- McQuilten, Z.
- Kirwan, B.A.
- Farkouh, M.E.
- Brooks, M.M.
- Lewis, R.J.
- Berry, L.R.
- Lorenzi, E.
- Gordon, A.C.
- Ahuja, T.
- Al-Beidh, F.
- Annane, D.
- Arabi, Y.M.
- Aryal, D.
- Kreuziger, L. Baumann
- Beane, A.
- Bhimani, Z.
- Bihari, S.
- Billett, H.H.
- Bond, L.
- Bonten, M.
- Brunkhorst, F.
- Buxton, M.
- Buzgau, A.
- Castellucci, L.A.
- Chekuri, S.
- Chen, J.T.
- Cheng, A.C.
- Chkhikvadze, T.
- Coiffard, B.
- Contreras, A.
- Costantini, T.W.
- Brouwer, S.
- Detry, M.A.
- Duggal, A.
- Džavík, V.
- Effron, M.B.
- Eng, H.F.
- Escobedo, J.
- Estcourt, L.J.
- Everett, B.M.
- Fergusson, D.A.
- Fitzgerald, M.
- Fowler, R.A.
- Froess, J.D.
- Fu, Z.
- Galanaud, J.P.
- Galen, B.T.
- Gandotra, S.
- Girard, T.D.
- Goodman, A.L.
- Goossens, H.
- Green, C.
- Greenstein, Y.Y.
- Gross, P.L.
- Haniffa, R.
- Hegde, S.M.
- Hendrickson, C.M.
- Higgins, A.M.
- Hindenburg, A.A.
- Hope, A.A.
- Horowitz, J.M.
- Horvat, C.M.
- Huang, D.T.
- Hudock, K.
- Hunt, B.J.
- Husain, M.
- Hyzy, R.C.
- Jacobson, J.R.
- Jayakumar, D.
- Keller, N.M.
- Khan, A.
- Kim, Y.
- Kindzelski, A.
- King, A.J.
- Knudson, M.M.
- Kornblith, A.E.
- Kutcher, M.E.
- Laffan, M.A.
- Lamontagne, F.
- Gal, G. Le
- Veerdonk, F.L. van de
- Middeldorp, S.
- Schouten, J.A.
- Pickkers, P.
- Webb, S.A.
- Zarychanski, R.
DOIAbstract
Item does not contain fulltextBACKGROUND: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. METHODS: In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number ...
Add to ORKG